Search results for "GLUCOCORTICOIDS"

showing 10 items of 162 documents

Mycophenolate mofetil and enteric-coated mycophenolate sodium in the treatment of pemphigus vulgaris and pemphigus foliaceus.

2014

What is known and objective: Pemphigus is a severe, potentially life-threatening autoimmune blistering disease. The use of corticosteroids has dramatically improved the prognosis and changed its course. However, current morbidity of pemphigus is largely iatrogenic, caused by side effects of the long-term, high-dose corticosteroid therapy that is necessary to sustain disease control. In order to minimize side effects, a range of corticosteroid-sparing immunosuppressive agents have been introduced, including mycophenolate mofetil (MMF) and enteric-coated mycophenolate sodium (EC-MPS). A systematic review was performed to evaluate the effectiveness of MMF and EC-MPS in the treatment of pemphig…

medicine.medical_specialtyEnteric-coated mycophenolate sodium mycophenolate mofetil mycophenolic acid pemphigus foliaceus pemphigus vulgaris therapyDermatologyMycophenolateMycophenolic acidimmune system diseasesmedicineSettore MED/35 - Malattie Cutanee E VenereeHumansEnteric coatedskin and connective tissue diseasesGlucocorticoidsPemphigus foliaceusintegumentary systembusiness.industryPemphigus vulgarisMycophenolate SodiumMycophenolic AcidPrognosismedicine.diseaseDermatologyPemphigusTreatment OutcomeDrug Therapy CombinationDermatologic AgentsbusinessImmunosuppressive AgentsPemphigusmedicine.drugBlistering disease
researchProduct

Steroid-resistant eosinophilic fasciitis successfully treated with addition of extracorporeal photopheresis.

2019

Eosinophilic fasciitis (EF) is an uncommon fibrosing disease of the fascia with characteristic cutaneous and hematologic manifestations. Although EF is most commonly treated with corticosteroids at the beginning, a considerable number of patients show an inadequate response and hence various therapeutic strategies have been tried, including extracorporeal photopheresis (ECP). We describe the case of a 66-year-old woman with steroid-resistant EF that improved significantly after ECP was added to her treatment regimen. To date, only six cases of this therapeutic strategy have been reported in English literature.

medicine.medical_specialtyFibrosing diseaseDermatology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineExtracorporeal PhotopheresisEosinophiliamedicineHumansFasciitisGlucocorticoidsTherapeutic strategyAgedTreatment regimenbusiness.industryGeneral MedicineFasciamedicine.diseaseDermatologySteroid resistantEosinophilic fasciitismedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisPhotopheresisFemalebusinessDermatologic therapy
researchProduct

Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion.

2020

Context: Glucocorticoid (GC) replacement therapy in patients with adrenal insufficiency (AI) is life saving. After over 50 years of conventional GC treatment, novel formulations are now entering routine clinical practice. Methods: Given the spectrum of medications currently available and new insights into the understanding of AI, the authors reviewed relevant medical literature with emphasis on original studies, prospective observational data and randomized controlled trials performed in the past 35 years. The Expert Opinion of a panel of selected endocrinologists was sought to answer specific clinical questions. The objective was to provide an evidence-supported guide, for the use of GC in…

medicine.medical_specialtyHydrocortisoneHormone Replacement TherapyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismlaw.inventionSettore MED/13 - Endocrinologia03 medical and health sciences0302 clinical medicineEndocrinologyGlucocorticoidRandomized controlled triallawPrednisonemedicineAdrenal insufficiencyOutpatient clinicHumansDosingIntensive care medicineGlucocorticoidsbusiness.industryAddison; Adrenal insufficiency; Cortisone acetate; Glucocorticoid; Hydrocortisone; Prednisonemedicine.diseaseItalyTransgender hormone therapyCortisone acetate030220 oncology & carcinogenesisPrednisoneObservational studybusinessMedical literaturemedicine.drugAddisonAdrenal InsufficiencyJournal of endocrinological investigation
researchProduct

Complex regional pain syndrome: An optimistic perspective.

2014

Complex regional pain syndrome (CRPS) presents with clinical symptoms that can no longer be explained by the initial trauma, including pain, sensory, motor, and trophic symptoms, and impairment of autonomic control of the limb. These symptoms spread distally and go beyond single nerve innervation territories. Typically, the symptoms change through the course of CRPS as a result of the varying pathophysiology. Diagnosis is made clinically after the rigorous elimination of other possible causes, and 3-phase bone scintigraphy can be a useful tool for confirming CRPS. In acute stages, inflammatory symptoms prevail and should be treated with anti-inflammatory agents (steroids), bisphosphonates, …

medicine.medical_specialtyImagery PsychotherapyImplosive TherapyPainMotor imageryOccupational TherapyNeuroplasticitymedicineHumansKetamineGlucocorticoidsPhysical Therapy ModalitiesAnalgesicsmedicine.diagnostic_testBone Density Conservation AgentsDiphosphonatesbusiness.industrySensory lossmedicine.diseaseComorbidityComplex regional pain syndromeBone scintigraphyAutonomic Nervous System DiseasesHyperalgesiaHyperalgesiaPhysical therapyKetamineNeurology (clinical)medicine.symptombusinessComplex Regional Pain Syndromesmedicine.drugNeurology
researchProduct

Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience

2021

AbstractWe conducted a meta-analysis of real-world studies on the 0.19 mg Fluocinolone Acetonide (FAc) intravitreal implant for chronic diabetic macular oedema (DMO), comparing these findings with the Fluocinolone Acetonide for Diabetic Macular Edema (FAME) study. The primary outcome was mean change of best corrected visual acuity (BCVA) at 24 months. Secondary outcomes were 36-month mean BCVA, mean central macular thickness (CMT) change, rates of eyes receiving supplementary intravitreal therapy, cataract surgery, intraocular pressure (IOP)-lowering drops and glaucoma surgery. Mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Nine real-world studies were included.…

medicine.medical_specialtyIntraocular pressuregenetic structuresSciencemedicine.medical_treatmentAnti-Inflammatory AgentsArticleMacular Edema03 medical and health sciences0302 clinical medicineDiabetes complicationsFluocinolone acetonideOphthalmologymedicineGlaucoma surgeryHumans030212 general & internal medicineGlucocorticoidsIntraocular PressureDrug ImplantsDiabetic RetinopathyMultidisciplinarybusiness.industryQRCataract surgeryRetinal diseaseseye diseasesConfidence intervalFluocinolone AcetonideDiabetic macular oedemaMeta-analysis030221 ophthalmology & optometryMedicinesense organsImplantbusinessmedicine.drugScientific Reports
researchProduct

Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort

2021

Abstract Objective The objective of this study was to use real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with systemic JIA (sJIA). Methods A retrospective multicentre study of children with sJIA was performed. Clinical features, laboratory parameters and adverse events were collected at baseline, and 6 and 12 months after starting canakinumab. The primary outcome measure of effectiveness was clinically inactive disease (CID) off glucocorticoids (GCs) treatment at 6 months. Results A total of 80 children from 15 Italian centres were analysed. Of the 12 patients who started canakinumab in CID while receiving anakinra, all maintained CID. Of the 68 …

medicine.medical_specialtyMultivariate analysissystemic juvenile idiopathic arthritisArthritisJuvenileAntibodies Monoclonal HumanizedcanakinumabAntibodiessystemic juvenile idiopathic arthritis.Settore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicineMonoclonalmedicinecanakinumab; clinically inactive disease; systemic juvenile idiopathic arthritis; Antibodies Monoclonal Humanized; Child; Glucocorticoids; Humans; Retrospective Studies; Arthritis Juvenile; Macrophage Activation SyndromeHumanscanakinumab clinically inactive disease systemic juvenile idiopathic arthritis Antibodies Monoclonal Humanized Child Glucocorticoids Humans Retrospective Studies Arthritis Juvenile Macrophage Activation SyndromePharmacology (medical)clinical inactive disease.Adverse effectChildHumanizedGlucocorticoidsRetrospective StudiesUnivariate analysisAnakinrabusiness.industryclinically inactive diseaseArthritisMacrophage Activation Syndromemedicine.diseaseArthritis JuvenileCanakinumabMacrophage activation syndromeCohortSystemic juvenile idiopathic arthritibusinessmedicine.drug
researchProduct

Use of Zoledronic Acid in a Neonate with Subcutaneous Fat Necrosis Complicated with Severe, Refractory Hypercalcemia.

2019

Objective Subcutaneous fat necrosis (SCFN) is a rare condition that may occur in the neonatal period. SCFN is an inflammatory disorder of the adipose tissue, usually found in full-term healthy infants who have a history of intrauterine or perinatal distress. It is usually a self-limited condition; however, in some cases, it can get complicated, leading to severe hypercalcemia that may be life-threatening. Study Design We report and describe a classic presentation of SCFN that led to severe hypercalcemia refractory to standard treatment. The diagnosis of SCFN was made based on the finding of subcutaneous nodules and of hypercalcemia. The serum calcium level reached 16.6 mg/dL. Hypercalcemia…

medicine.medical_specialtyNecrosisTerm BirthDrug ResistanceSubcutaneous FatAdipose tissuehypercalcemia; neonate; subcutaneous fat necrosis; zoledronic acid; Bone Density Conservation Agents; Calcium; Drug Resistance; Fat Necrosis; Female; Furosemide; Glucocorticoids; Humans; Hypercalcemia; Infant Newborn; Methylprednisolone; Sodium Potassium Chloride Symporter Inhibitors; Subcutaneous Fat; Term Birth; Zoledronic AcidGastroenterologyMethylprednisoloneZoledronic AcidRefractorySodium Potassium Chloride Symporter InhibitorsFurosemideInternal medicinesubcutaneous fat necrosismedicineHumansFat necrosisFat NecrosisGlucocorticoidsBone Density Conservation Agentsbusiness.industryStandard treatmentInfant NewbornObstetrics and GynecologyFurosemideInfantmedicine.diseaseNewbornZoledronic acidMethylprednisolonePediatrics Perinatology and Child HealthHypercalcemiaCalciumFemalemedicine.symptomneonatebusinessmedicine.drugAmerican journal of perinatology
researchProduct

Dexamethasone suppresses eNOS and CAT-1 and induces oxidative stress in mouse resistance arterioles

2004

Long-term treatment with glucocorticoids is associated with mild to moderate hypertension. We reported previously that downregulation of endothelial NO synthase (eNOS) expression and activity is likely to contribute to this increase in blood pressure. In the present study, we tested the effects of dexamethasone on the vasodilation of microvascular arterioles using implanted dorsal skin-fold chambers in anesthetized C57BL/6J mice. Experiments were performed on control mice or on mice treated with dexamethasone (0.1–3 mg/kg of body wt). Endothelium-dependent vasodilation in response to ACh (0.1–10 μM) was reduced by dexamethasone in a dose-dependent fashion. Comparable inhibition was seen in …

medicine.medical_specialtyNitric Oxide Synthase Type IIIPhysiologyNitric Oxide Synthase Type IIAscorbic AcidBiologyArgininemedicine.disease_causeAntioxidantsDexamethasoneMicrocirculationMiceDownregulation and upregulationEnosArteriolePhysiology (medical)medicine.arteryInternal medicinemedicineAnimalsHumansGlucocorticoidsCells CulturedNitritesDexamethasoneCationic Amino Acid Transporter 1NitratesMyocardiumEndothelial Cellsbiology.organism_classificationAcetylcholineMice Inbred C57BLVasodilationNitric oxide synthaseArteriolesOxidative StressEndocrinologybiology.proteinVascular ResistanceNitric Oxide SynthaseCardiology and Cardiovascular MedicineOxidative stressGlucocorticoidmedicine.drugAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct

D-penicillamine in Wilson's disease presenting as acute liver failure with hemolysis.

1982

Wilson's disease in a young woman presenting with an acute course is described. The clinical manifestations were fulminant hepatic failure associated with marked intravascular hemolysis. Immediate D-penicillamine and high-dose steroid therapy did not influence the course of the disease. Necropsy revealed an increased hepatic copper content and cirrhosis with extensive necrosis of the liver.

medicine.medical_specialtyPathologyCirrhosisAdolescentPhysiologyDiseaseGastroenterologyHemolysisFulminant hepatic failureHepatolenticular DegenerationInternal medicinemedicineHumansGlucocorticoidsbusiness.industryLiver DiseasesPenicillaminePenicillamineGastroenterologyLiver failureCeruloplasminHepatologyMiddle Agedmedicine.diseaseHemolysisWilson's diseaseAcute DiseaseFemalebusinessCoppermedicine.drugDigestive diseases and sciences
researchProduct

The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy

2015

Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease, though severe forms are rare. Management of GO is often suboptimal, largely because available treatments do not target pathogenic mech anisms of the disease. Treatment should rely on a thorough assessment of the activity and severity of GO and its impact on the patient's quality of life. Local measures (artificial tears, ointments and dark glasses) and control of risk factors for progression (smoking and thyroid dysfunction) are recommended for all patients. In mild GO, a watchful strategy is usually sufficient, but a 6-month course of selenium supplementation is effective in improving mild manifestations …

medicine.medical_specialtyPediatricsCyclosporine; Eyelid surgery; Glucocorticoids; Graves' orbitopathy; Orbital decompression; Orbital radiotherapy; Rituximab; Selenium; Squint surgeryEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMedizin030209 endocrinology & metabolismDiseaseGuidelines03 medical and health sciencesGraves' orbitopathySeleniumEndocrinology0302 clinical medicineQuality of lifemedicineEyelid surgeryOrbital radiotherapyGlucocorticoidsbusiness.industryCumulative doseThyroideye diseasesSurgeryDiabetes and MetabolismOrbital decompressionArtificial tearsmedicine.anatomical_structureMethylprednisolone030221 ophthalmology & optometryCyclosporineRituximabSquint surgerybusinessRituximabWatchful waitingCyclosporine; Eyelid surgery; Glucocorticoids; Graves' orbitopathy; Orbital decompression; Orbital radiotherapy; Rituximab; Selenium; Squint surgery; Endocrinology Diabetes and Metabolismmedicine.drug
researchProduct